entrepreneurship Archives - Sanford Burnham Prebys
Institute News

With a little help from my friends

AuthorScott LaFee
Date

October 23, 2023

Sanford Burnham Prebys’ latest gala celebrated an old, dear friend, a brand-new vision and a crowd in fab form.

The event began with an evening filled with gratitude, recognition and, well, a look to the future.

On Saturday night, more than 280 friends, faculty and supporters of Sanford Burnham Prebys gathered at the Estancia La Jolla Hotel & Spa to celebrate the event’s theme: “A Future Filled with Discoveries and Cures.”

But more specifically, attendees paid homage to two men: philanthropist T. Denny Sanford, whose long and enduring support has helped shape and sustain Sanford Burnham Prebys; and David Brenner, MD, the institute’s (newish) president and CEO, who is using Sanford’s most recent gift to implement a bold, new strategic plan.

“Denny has always been a friend, guide and mentor,” said Brenner. “He has made much of what I do—what we will do together—possible.”

It was an evocative evening, with sartorially splendid guests arriving to a scene best described as a 1960s-era “lavish London lounge,” featuring vibrant colors and rich materials, roaming magicians; and a strolling trio of trumpet, trombone and tambourine players.

The festivities formally opened with welcoming remarks from Honorary Trustee Malin Burnham, who noted that “the Institute is at a dramatic time and place—with new faces, a new vision and an old friend.”

Burnham, who has served on the Board since 1982, noted that Sanford, who could not attend the event, was watching a live stream of the event from his home in South Dakota. “He can see and hear us,” Burnham said, waving.

Following dinner, Bill Gerhart, the current chair of the Sanford Burnham Prebys Board of Trustees, stepped up to acknowledge Sanford’s long history of support to the Institute and all of the donors, supporters and staff in the room who “make things happen”; and to introduce Brenner as “a guy who really can make things happen.”

Brenner, who also holds the Donald Bren Chief Executive Chair, spoke eloquently about Sanford before briefly detailing strategic plans for the Institute, one intended to put Sanford Burnham Prebys at the forefront of the current biomedical research revolution.

Malin and Roberta Burnham at the 2023 Special Gala

“Here’s my elevator speech,” Brenner said, inviting attendees to follow along by reading a program insert.
 

Our Mission

We translate science into health.

Biomedical research is undergoing a revolution, driven by big data, artificial intelligence and other emerging technologies.

We are uniquely positioned to lead because…

We study the toughest diseases: cancer, heart, mind and metabolic.
We are forward-looking, unafraid of change or challenge.
We are collaborative, flexible, multi-disciplinary and team-focused.
We embrace data science.
We promote entrepreneurship.
We are central to a vibrant, local biomedical community.

A key part of the strategic plan, Brenner said, is embodied in the new cadre of young scientists recently recruited to Sanford Burnham Prebys from “some of the best labs at some of the best institutions in the country.”

Their recruitment (and new hires to follow) are the benefit of a $70 million gift from Sanford to create up to 20 new faculty positions in the next few years in diverse research areas including cancer, neurodegeneration and computational biology.

Four of the six new scientists were in attendance: Sanju Sinha, PhD, from the National Cancer Institute; Sanjeev Ranade, PhD, from Gladstone Institutes; Kelly Kersten, PhD, from UC San Francisco; and Xiao Tian, PhD, from Harvard Medical School.

Sinha joined the Institute in June. Kevin Tharp, PhD, from UCSF, arrives in November. The other four researchers, including Shengjie Feng, PhD, from the Howard Hughes Medical Institute and UCSF, officially join Sanford Burnham Prebys in January 2024.

Brenner then introduced a special four-minute video: a visual thank-you to Sanford and a visionary peek at the Institute’s next steps and aspirations. The video ended with a standing ovation.

With the lights still dim, the entertainment portion of the evening began: a live reimagining of John Lennon’s beloved 1971 song “Imagine,” dedicated to Sanford and the new strategic plan.

“Imagine there’s no illness
It’s easy if we try…”

“You may say Denny’s a dreamer
But he’s not the only one.
We hope someday you’ll join us
And the world can be as one.”

 

Then it was the Beatles’ tribute band “Abbey Road Show,“ a 70-minute set of music and narration chronicling the Fab Four, followed by nightcaps, conversation and thoughts about the next day—when the future begins.
 

Note: For your own free, handy, wallet-sized mission card or more information about how you can support Sanford Burnham Prebys, please contact the Philanthropy team.

2023 Special gala homepage graphic
Institute News

Sanford Burnham Prebys hosts top life-science VC firm to learn the secrets of getting funded

AuthorMonica May
Date

February 26, 2019

There’s no way around it: Developing medicine is costly. The average drug takes about $2.6 billion to develop through FDA approval, according to the Tufts Center for the Study of Drug Development. With a price tag that high, securing venture capital (VC) funding is critical for turning a scientist’s discovery into reality.

This month, Kirsten Leute of Osage University Partners (OUP), a top life-science VC firm, spoke to SBP scientists about best practices and common pitfalls when making a VC pitch. 

Anjali Gupta, a graduate student in the laboratory of Karen Ocorr, PhD, assistant professor at SBP, attended the presentation and explained why the insights are so valuable. 

“Drug discovery is a complex and expensive process. It’s important to understand how bench science can be translated into successful products—in this case, potentially life-saving medicines,” says Gupta. “At SBP, scientists are investigating the underlying causes of rare, debilitating diseases and looking for cures for cancer, heart failure, Alzheimer’s disease and more by discovering novel therapeutic targets, signaling pathways, and mechanisms. By knowing the funding options and strategies available, we can make more informed decisions about our discoveries and increase the probability of developing our research into medicines for patients who need these treatments.” 

Below are seven tips Leute shared to help scientists navigate building a start-up and getting it funded. 

  1. It’s all about the team. VC firms look for an investable management team. Is this the leadership team’s first start-up? Or are they serial entrepreneurs? What skills do they have, and which do they lack? Being a novice entrepreneur isn’t a funding deal breaker—but you may want to consider supplementing your team with experienced partners. 
  2. Pick your partners wisely. The most important relationship decision you make in your life is choosing your significant other. The second most important? Finding your business partners. Many founders bring in colleagues who work down the hall—or even neighbors. But it’s most important to know how you work with one another. Can you argue respectfully? Do you trust that you all have the company’s best interest in mind? 
  3. Do your homework. Before you approach a VC firm, make sure you know its investment focus. Does it specialize in pre-clinical or late-stage assets? Does it lead investments or follow on? In recent years, we’ve seen more crossover investing: firms that invest in a company prior to an initial public offering (IPO). A firm’s focus may shift over time, so make sure to stay up to speed. 
  4. Contact the right person. At most firms, each individual has a specialty, such as immunotherapy. So, if you have an immunotherapy product, make sure you’re contacting the individual who works in that area—and not the person who focuses on robotics, for example. 
  5. Mind your budget. VC firms see a lot of pitches. They can spot it if you haven’t budgeted enough—or are budgeting too much—for an activity. If you’re a first-time entrepreneur, it’s best to hire a consultant or find a mentor who can help (see the resources below).
  6. Ask for advice. VC firms love giving advice, which can help strengthen your ultimate pitch for funding. This will also stimulate their interest in your company. Your institute’s technology transfer office may also have helpful resources and connections. 
  7. Show all your cards—even the negative ones. VC firms hate surprises. Make sure you address any concerns or risks up front. The truth always comes out eventually. 

Ready to get your discovery funded? Below are additional resources and reading materials. 

Resources: 

Reading: 

  • Life Sci VC: blog about all things biotech venture capital by scientist turned early-stage venture capitalist Bruce Booth 
  • The Long Run: veteran biotech reporter Luke Timmerman conducts in-depth interviews with biotech newsmakers 
  • Nature’s bioentrepreneur: practical advance and guidance for starting a biotech company 
Institute News

SBP scientist recognized by Biocom for contributions to San Diego life science industry

AuthorMonica May
Date

September 25, 2018

Tao Long, PhD, assistant professor in the Bioinformatics and Structural Biology Program at Sanford Burnham Prebys Medical Discovery Institute (SBP), has been named a 2018 Life Science Catalyst by Biocom, the association representing the California life science industry.

This annual award celebrates up-and-coming individuals in the life science industry—including scientists, entrepreneurs, investors, corporate leaders and business advisers—who are making a lasting and positive mark on Southern California’s life science industry prior to their 40th birthdays. Read the full list of winners.

Scientists know that individuals’ genetic makeups and gut microbiomes play important roles in human health. But sorting through genomic and clinical data is technologically complex. Long and her team are developing bioinformatics and machine-learning algorithms to help uncover links between our genes as well as the genes of the trillions of microbes that live in our gut and disease. This work could help us learn more about health conditions ranging from cancer to Alzheimer’s disease.

“Marked by their contributions to research, discovery and entrepreneurship in San Diego and Los Angeles, this year’s Life Science Catalyst Award recipients showcase the up-and-coming leaders who are transforming the life science industry,” says Joe Panetta, president and CEO of Biocom. “Biocom is honored to recognize these people who are utilizing their skill sets to positively impact human health across the globe.”

The 17 award winners will be featured in the fall edition of Biocom’s LifeLines magazine and honored during the December Biocom Board of Directors meeting.

Interested in keeping up with SBP’s latest discoveries, upcoming events and more? Subscribe to our monthly newsletter, Discoveries.

Institute News

The business of science

AuthorKristen Cusato
Date

October 27, 2017

Bringing life sciences and investors together is a primary goal of the first San Diego Innovation Showcase, held Thursday, October 26th at the Hilton La Jolla Torrey Pines. Sanford Burnham Prebys Medical Discovery Institute (SBP), among other local institutions, presented some of its top scientists and spin off companies at the all-day event. The Innovation Showcase is sponsored by the newly formed San Diego Innovation Council whose mission is to promote growth through innovation, entrepreneurial activities and education.

SBP was well represented at the event, with principals from five spin-off companies presenting their successes. SBP’s Nick Cosford, PhD, and Aman Mann, PhD, shared news about their companies, and Vice President of Business Development Lee Blumenfeld, MD, and Director of Business Development Scott McNinch, came to network.

“SBP is here to present a number of start-up companies to investors,” said McNinch. “Many investors here are interested in innnovative science that lead to spin-outs.”

“For us, it’s about getting exposure and making our presence known,” said Mann, who works in the lab of Erkki Ruoslahti, MD, PhD, a distinguished professor at SBP. “It’s valuable to meet other entrepreneurs and learn from each other about best practices and licensing, for example.”

In this climate, scientists interested in partnering or spinning off a company have to become business savvy.

McNinch says, “We talk about translational research ultimately benefiting patients. One way is to transition promising research into companies that will turn out a product or service that will help patients.”

The event featured leaders and entrepreneurs from the therapeutics/diagnostics, software/electronics and materials/engineering fields. Other organizations that participated included UC San Diego, Salk and University of San Diego.

Institute News

Aspiring scientists tackle big data at Sanford Burnham Prebys Medical Discovery Institute

AuthorGuest Blogger
Date

June 24, 2016

Growing up, Courtney Astore was inquisitive about science and technology. So when she had the opportunity to participate in middle school science fairs, she jumped at the chance. In high school, Astore’s research in behavioral and social science, medicine and elaborate statistical algorithms led to her being a finalist at the Intel International Science and Engineering Fair three times.

Today, as an incoming sophomore at the University of Central Florida (UCF), Astore is majoring in Biotechnology with a focus on Bioinformatics. Together, with her lifelong friend Rebecca Elsishans at the University of Florida, she plans to launch a start-up company called Enasci-x that will use genetic analysis to aid in vaccine development.

Executives at UCF’s business incubator contacted Leslie Molony, PhD, senior director of Business Development for Sanford Burnham Prebys Medical Discovery Institute’s (SBP)  Lake Nona campus to inquire about providing  training to aspiring scientists enrolled in the National Science Foundation- iCorps™ funded  LaunchPad program.

The LaunchPad program fosters entrepreneurial research designed to help the commercialization of technology. Molony guided Astore and Elsishans in the biological science and business aspects of forming a start-up for their first product-in-development called Genes4Vaccines.

Her students received guidance on a top-level list of ‘how-to’s’

  • how to understand protein structures
  • how to generate data that can lead to new drug discovery
  • how to define new products and commercialize them
  • how to develop business plans and ‘pitching’ strategies

“Courtney and Rebecca are phenomenal young women who are very eager to understand how the medical research process—vaccine discovery–can lead to commercial products,” said Molony.  “They have great potential to become software service providers, or to use their talents to discover new vaccine targets that may lead to partnerships with pharmaceutical companies.”

“In terms of where we are today and how we’ve been able to map out what we need to do, we couldn’t have done any of this without Dr. Molony,” said Astore. “Her drug discovery background and business development expertise have opened our eyes to the potential of what we can accomplish, and what we need to do to get there. We know our next big steps are to finalize our minimum value product, get data validation in the lab and then attract investors.”

Big data for medical research, adds Molony, is a growing niche in the field of infectious disease where vaccine and therapy needs arise quickly and unexpectedly.

To augment her student’s training, she connected Astore with Fraydoon Rastinejad, PhD, professor in SBP’s Center for Metabolic Origins of Disease at Lake Nona who offered her a summer internship where she’ll be collecting data and analyzing human disease databases.

“Dr. Rastinejad is one of the most renowned researchers in the field, and I’m honored to have the opportunity to work with him.  My internship will give me a deeper base of scientific knowledge to advance my research,” said Astore. “To work hands-on in his lab, analyzing data that recognizes patterns and clues to disease development is a dream come true.”

This post was written by Jackie Kelvington

Related:
Genes4Vaccines – UCF I-Corps